Keywords: bayer, licenses, ardea, meks, up, 407m, germany
Bayer licenses Ardea's MEKs for up to $407M
Article | 29 April 2009
Germany's Bayer HealthCare AG has entered into an accord with USA-based Ardea Biosciences focused on the development of small-molecule mitogen-activated ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
